Michael Dunn

Background: Quality improvement (QI) interventions may reduce the incidence and severity of Intraventricular Hemorrhage (IVH) in the population of inborn micropremature infants (born at ≤26 weeks’ gestation) with the goal of improving outcomes in this high-risk population. Methods: A multidisciplinary team reviewed the current literature to develop a site-specific brain protective bundle. Baseline data were collected from June 2014 to February 2015, with interventions occurring from March 2015 to December 2015. The period of sustainability was assessed from January 2016 to December 2023. Control charts were used to analyze the effect of the interventions. Outcome measures included all grades of IVH, periventricular leukomalacia (PVL), necrotizing enterocolitis (NEC), and spontaneous intestinal perforations (SIP). Results: Brain care initiatives decrease the rate of severe IVH in the inborn micropremature infant population from a baseline of 21% to 6.45% with a sustained rate of 4.5% with no change to balancing measures. Conclusions: Brain-protective initiatives such as midline head positioning and minimal handling are associated with a significant and sustained reduction in severe IVH among inborn micropremature infants.

Objective Indomethacin and hydrocortisone prophylaxis may improve clinical outcomes when administered to extremely preterm neonates. However, they cannot be administered together and there is limited evidence to support which therapy may be most beneficial. Study Design: A retrospective matched cohort study was conducted in neonates less than 28 weeks gestational age (GA) and birth weight less than 1000 grams who received prophylaxis with indomethacin or hydrocortisone. Multivariable logistic regression analysis was used to evaluate clinical outcomes. Results Among 177 neonates, 40 treated with prophylactic hydrocortisone were matched with 137 neonates treated with prophylactic indomethacin. Indomethacin-treated neonates had significantly lower incidence of PDA, PDA requiring surgical closure, late-onset sepsis, and higher rates of survival without oxygen supplementation at discharge. There was no difference in mortality, BPD, NEC, or IVH. Conclusion When compared to hydrocortisone, indomethacin prophylaxis was associated with more favorable outcomes.

A survey was conducted among Canadian tertiary neonatal intensive care units. Of the 27 sites who responded, 9 did not have any form of antimicrobial stewardship, and 11 used vancomycin for empirical coverage in late-onset-sepsis evaluations. We detected significant variations in the diagnostic criteria for urinary tract infection and ventilator-associated pneumonia.

Background: To estimate hand hygiene compliance using electronic hand hygiene monitoring, the number of hand hygiene opportunities (HHOs) per period must be known in a given setting. Data on the number of HHOs in a neonatal ICU (NICU) are limited. We measured HHOs per hour and identified factors that may influence the number of HHOs per hour to calibrate compliance estimates for electronic hand hygiene monitoring. Methods: The study was conducted in 2 large NICUs in Ontario, Canada (72 and 42 beds, respectively). We centrally trained observers to identify HHOs using the Ontario-based “Four Moments of Hand Hygiene,” which is similar to combining moments 4 and 5 of the WHO “Five Moments of Hand Hygiene.” To apply the moments of hand hygiene to the NICU setting, the following modifications were made: moment 1 was entering the incubator or contact with anything within the ‘baby space’ directly around the incubator, and moment 4 was when hands exited the incubator and, as such, the ‘baby space.’ Using a standardized tool, the investigators conducted direct observation of HHOs during randomized observation periods from July 1, 2022, to January 9, 2023. In addition to HHOs, data on covariables potentially associated with the frequency of HHOs were collected: time and day of the week, acuity, additional precautions, corrected gestational age, and private versus multibed room or open pod. Results: We audited HHOs for 146 hours including 26 at site A and 120 at site B. Overall, 804 HHOs (69.2%) occurred during weekdays and 739 (63.6%) occurred during day shifts from 7:00 a.m. to7:00 p.m. The most frequent moments of hand hygiene were moment 1 (47.8%, before contact) and moment 4 (36.8%, after contact). The average numbers of HHOs were 7.8 per hour overall, 7.6 per hour on weekdays, 7.7 per hour on weekends, 8.8 per hour on day shifts, and 6.8 per hour on night shifts. The breakdown of HHOs by profession was 92.8% nurses, 0.6% physicians, 4.5% allied health, and 2.1% for others. Discussion: The rate of HHOs in NICU varied over a 24-hour period and was similar between 2 different NICUs. Evenings and weekends had considerably fewer average HHOs, and peaks were observed following nursing shift changes. The rate of HHOs may be influenced by other factors including unit design, patient acuity, and use of transmission-based precautions. Further analysis using a Poisson regression model will help to explore these factors and to calibrate electronic monitoring for this population. Disclosures: None

Objective To compare short term respiratory outcomes in preterm infants treated with bovine lipid extract surfactant or poractant alfa. Study design Prospective comparative effectiveness cohort study of infants <32 weeks’ gestational age requiring surfactant in thirteen centers. Each center provided bovine lipid extract surfactant for a set period of time in the year 2019 and then changed to poractant alfa for the remainder of the year. The primary outcome was total duration of respiratory support. Result 968 infants were included. 494 received bovine lipid extract surfactant and 474 received poractant alfa. No difference was observed in the total duration of respiratory support (mechanical ventilation or non-invasive) (median 38 vs 40.5 days), need to re-dose surfactant, bronchopulmonary dysplasia, survival to discharge, or length of admission. Conclusion In this pragmatic study, we did not identify any difference in short term outcomes between the groups based on the type of surfactant received.

Inhaled corticosteroids (ICS) offer targeted treatment for bronchopulmonary dysplasia (BPD) with minimal systemic effects compared to systemic steroids. However, dosing of ICS in the management of infants at high-risk of developing BPD is not well established. The objective of this study was to determine an effective dose of ICS for the treatment of ventilator-dependent infants to facilitate extubation or reduce fractional inspired oxygen concentration. Forty-one infants born at < 32 weeks gestational age (GA) or < 1250 g who were ventilator-dependent at 10–28 days postnatal age were included. A non-randomized dose-ranging trial was performed using aerosolized inhaled beclomethasone with hydrofluoralkane propellant (HFA-BDP). Four dosing groups (200, 400, 600 and 800 μg twice daily for 1 week) with 11, 11, 10 and 9 infants in each group, respectively, were studied. The primary outcome was therapeutic efficacy (successful extubation or reduction in FiO2 of > 75% from baseline) in ≥60% of infants in the group. Oxygen requirements, complications and long-term neurodevelopmental outcomes were also assessed. The median age at enrollment was 22 (10–28) postnatal days. The primary outcome, therapeutic efficacy as defined above, was not achieved in any group. However, there was a significant reduction in post-treatment FiO2 at a dose of 800 μg bid. No obvious trends were seen in long-term neurodevelopmental outcomes. Therapeutic efficacy was not achieved with all studied doses of ICS. A significant reduction in oxygen requirements was noted in ventilator-dependent preterm infants at 10–28 days of age when given 800 μg of HFA-BDP bid. Larger randomized trials of ICS are required to determine efficacy for the management of infants at high-risk for development of BPD. This clinical trial was registered retrospectively on clinicaltrials.gov. The registration number is NCT03503994 .